CompletedPhase 2

Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis

United States186 participantsStarted 2017-08-01

Plain-language summary

This is a multicenter, randomized, double-blind, double-dummy, active-controlled, dose-finding study to compare the efficacy, safety and tolerability of oral SCY-078 versus oral fluconazole in adult female subjects 18 years and older with moderate to severe Acute Vulvovaginal Candidiasis (AVVC). Approximately 180 eligible subjects (30 subjects per treatment group) will be enrolled and randomized into the study.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Subject is a female of at least 18 years of age
✓. Subject has a diagnosis of symptomatic AVVC at baseline including a positive microscopic examination with 10% KOH in a vaginal sample revealing yeast forms (hyphae/pseudohyphae) or budding yeasts, and vaginal pH (≤4.5)

Exclusion criteria

✕. Subject has any vaginal condition other than AVVC that may interfere with the diagnosis or evaluation of response to therapy, such as suspected or confirmed concurrent causes of vulvovaginitis and/or cervicitis (mixed infection)
✕. Need for systemic and/or topical (vaginal) antifungal treatment, including prescription or over-the-counter products during the study and treatment for VVC 28 days prior to randomization
✕. Subject is actively menstruating at the time of the Baseline visit.
✕. Subject has uncontrolled diabetes mellitus.
✕. Subject has a vaginal sample with pH \>4.5.
✕. Subject has a history of or an active cervical/vaginal cancer.

What they're measuring

Clinical Cure (Complete Resolution of Signs and Symptoms)

Timeframe: 8-12 days

Trial details

NCT IDNCT03253094

SponsorScynexis, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2018-05-04

Results submitted2021-06-30

View on ClinicalTrials.gov More Candida Vulvovaginitis trials